Close Menu

NEW YORK – Qiagen said after the close of the market on Monday that it is collaborating with Amgen to develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer (NSCLC).

The Therascreen CDx test will use real-time PCR to identify patients with cancers that have the KRAS G12C mutation, one of the most common causes of cancer. The RAS gene family includes the most frequently mutated oncogenes in cancers with KRAS being the most prevalent driver in NSCLC.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.